AgingResearch.NewsJoin free

No phaseRecruitingAge-related condition

Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation (RESEARCH)

Impact of Resveratrol on Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 in Postmenopausal Women With Chronic Coronary Syndrome: The RESH Randomized Trial

Sponsor
InCor Heart Institute (Academic or other)
Enrolment
80 planned
Conditions
Coronary Artery Disease (CAD); Menopause; Hormones
Interventions
Trans-resveratrol, 1000 mg daily for 90 days; Placebo
Ages
adults, older adults
Registry
NCT07865377

Full record on ClinicalTrials.gov

From the registry

Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.

Primary outcomes

  • 1. Sirtuin-1 and sirtuin-3
  • Estradiol
  • Estrone
  • SHBG

History

  1. Primary completion expected

  2. Last registry update

  3. Registered

  4. Started